8-K filing — Crinetics Pharmaceuticals, Inc. (CRNX)
Filed: 2026-08-19 AccNo: 0001140361-26-033738 Size: 425 KB Item 8.01: Other Events
Read original at edgarStocks · News reference
Crinetics Will Not Provide Updated Guidance, Withdraws Prior Outlook Following Vertex Deal Announcement
Business Outlook and Conference CallIn light of Crinetics’ July 6, 2026 announcement regarding the proposed transaction with Vertex, Crinetics will not be providing updated guidance and is withdrawing its previously
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 3, 2026, 8:52 PM
- Checked
- Aug 3, 2026, 8:52 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Top 3 Health Care Stocks That May Implode In August
3 health care stocks with high momentum could be overbought. Crinetics Pharmaceuticals (CRNX) has RSI of 90.6, Alamar Biosciences (ALMR) at 86.8, and Halozyme Therapeutics (HALO) at 81.7.
Read original at benzingaCrinetics Pharmaceuticals Q2 EPS $(1.14) Beats $(1.24) Estimate, Sales $25.118M Beat $14.840M Estimate
Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(1.14) per share which beat the analyst consensus estimate of $(1.24) by 8.06 percent. This is a 7.32 percent increase over losses of $(1.23) per
Read original at benzinga